Ignite Creation Date:
2024-05-06 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 2:18 PM
Study NCT ID:
NCT05126290
Status:
RECRUITING
Last Update Posted:
2024-02-21
First Post:
2021-11-02
Brief Title:
CTNNA1 Familial Expansion Study
Sponsor:
Abramson Cancer Center at Penn Medicine
Organization:
Abramson Cancer Center at Penn Medicine
Study Overview
Official Title:
CTNNA1 Familial Expansion CAFÉ Study
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CAFÉ
Brief Summary:
The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants
Detailed Description:
The CAFÉ Study aims to determine the degree to which loss-of-function variants in the CTNNA1 gene are associated with hereditary cancers including gastric cancer breast cancer as well as other cancers that may be associated with this gene By obtaining personal and family history information from individuals who carry a CTNNA1 loss-of-function variant and their family members this study will aim to better define CTNNA1 associated cancer risks and determine whether there is a genotypephenotype correlation for CTNNA1 loss-of-function variants This information will be important for the future cancer risk management of individuals who carry a CTNNA1 loss-of-function variant
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 844070 | OTHER | UPENN IRB | None |